Precision oncology M&A just got a $10.6 billion exclamation point.
On June 9, 2026, GSK announced it had entered a definitive agreement to acquire Nuvalent, Inc. (Nasdaq: NUVL), a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company, for $124 per share in cash — a 40% premium to Nuvalent’s last closing price. Shares in Nuvalent jumped nearly 40% in premarket trading. The deal, net of cash acquired, represents roughly $9.4 billion out of GSK’s pocket, and it’s being called GSK’s largest acquisition in over a decade.
Slight tangent, but it matters: this is GSK’s third major acquisition in the first six months of 2026. That cadence doesn’t happen without urgency. Under new CEO Luke Miels — who took over from Emma Walmsley in January — GSK has made clear it’s willing to pay up for late-stage oncology assets rather than wait for internal discovery to fill pipeline gaps driven by looming patent expirations.
What’s Actually in the Box
The deal centers on two late-stage, next-generation lung cancer drugs currently under FDA review:
- Zidesamtinib (NVL-520) — a highly selective ROS1 inhibitor with FDA Breakthrough Therapy designation, designed to address emergent treatment resistance and brain metastases that limit existing therapies. PDUFA target action date: September 18, 2026.
- Neladalkib (NVL-655) — an ALK inhibitor currently under NDA review, targeting ALK-positive non-small cell lung cancer patients who’ve already been treated with multiple prior TKIs. FDA decision expected in November 2026.
Bank of America analysts estimated the two drugs could bring in peak annual sales of $3 billion to $4 billion combined. If both receive FDA approval this year — which is squarely in the base case — GSK could have two potential blockbusters launching within months of closing the deal. The acquisition is expected to close in Q3 2026.
What’s interesting is what this signals beyond GSK itself. The $10.6 billion price tag — paid for a company that has not yet generated commercial revenue — reflects how aggressively large pharma is competing for precision oncology assets with validated targets and clean clinical profiles. Nuvalent’s drugs weren’t just novel; they were designed from the ground up to overcome the resistance mechanisms that doom the drugs they’re meant to replace. That’s the kind of differentiation that commands a premium.
The deal also adds an early-stage HER2 lung cancer drug, NVL-330 — a brain-penetrant HER2-selective inhibitor currently in Phase 1 trials — and several discovery-stage programs to GSK’s pipeline. Three products in lung cancer in a single transaction, with a platform capable of expanding further.
The Risks Aren’t Small
Neladalkib faces real competitive pressure. Pfizer’s Lorbrena and Roche’s Alecensa both target the ALK mutation, and carving out meaningful market share against established, well-funded competitors will require strong clinical differentiation and aggressive launch execution. Analysts flagged this dynamic immediately after the deal broke.
There’s also the broader question of whether GSK is paying a peak-of-cycle M&A premium in oncology. The biopharma M&A wave of 2026 has been relentless — driven by patent cliffs across the industry — and that kind of competitive bidding environment tends to favor sellers, not acquirers.
Still, the deeper story here may not be about GSK specifically. It’s about what happens when two late-stage, best-in-class oncology assets approach FDA decisions simultaneously — and what that signals about where the next wave of precision medicine value creation is being built. That conversation is just getting started.
